Literature DB >> 26981612

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Paola Moreno1, Irene Ramos-Álvarez1, Terry W Moody2, Robert T Jensen1.   

Abstract

INTRODUCTION: Despite remarkable advances in tumor treatment, many patients still die from common tumors (breast, prostate, lung, CNS, colon, and pancreas), and thus, new approaches are needed. Many of these tumors synthesize bombesin (Bn)-related peptides and over-express their receptors (BnRs), hence functioning as autocrine-growth-factors. Recent studies support the conclusion that Bn-peptides/BnRs are well-positioned for numerous novel antitumor treatments, including interrupting autocrine-growth and the use of over-expressed receptors for imaging and targeting cytotoxic-compounds, either by direct-coupling or combined with nanoparticle-technology. AREAS COVERED: The unique ability of common neoplasms to synthesize, secrete, and show a growth/proliferative/differentiating response due to BnR over-expression, is reviewed, both in general and with regard to the most frequently investigated neoplasms (breast, prostate, lung, and CNS). Particular attention is paid to advances in the recent years. Also considered are the possible therapeutic approaches to the growth/differentiation effect of Bn-peptides, as well as the therapeutic implication of the frequent BnR over-expression for tumor-imaging and/or targeted-delivery. EXPERT OPINION: Given that Bn-related-peptides/BnRs are so frequently ectopically-expressed by common tumors, which are often malignant and become refractory to conventional treatments, therapeutic interventions using novel approaches to Bn-peptides and receptors are being explored. Of particular interest is the potential of reproducing with BnRs in common tumors the recent success of utilizing overexpression of somatostatin-receptors by neuroendocrine-tumors to provide the most sensitive imaging methods and targeted delivery of cytotoxic-compounds.

Entities:  

Keywords:  Bombesin; CNS tumor; breast cancer; cancer; gastrin-releasing peptide; lung cancer; nanoparticles; prostate cancer; targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 26981612      PMCID: PMC5067074          DOI: 10.1517/14728222.2016.1164694

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  207 in total

1.  Peptide modified nanocarriers for selective targeting of bombesin receptors.

Authors:  Antonella Accardo; Rosalba Mansi; Anna Morisco; Gaetano Mangiapia; Luigi Paduano; Diego Tesauro; Aurel Radulescu; Michela Aurilio; Luigi Aloj; Claudio Arra; Giancarlo Morelli
Journal:  Mol Biosyst       Date:  2010-02-09

2.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Taichi Nakamura; Robert T Jensen
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

4.  Bombesin analogues for gastrin-releasing peptide receptor imaging.

Authors:  Prasant K Nanda; Usha Pandey; Brienne N Bottenus; Tammy L Rold; Gary L Sieckman; Ashley F Szczodroski; Timothy J Hoffman; Charles J Smith
Journal:  Nucl Med Biol       Date:  2012-01-20       Impact factor: 2.408

5.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study.

Authors:  C Van de Wiele; F Dumont; R Vanden Broecke; W Oosterlinck; V Cocquyt; R Serreyn; S Peers; J Thornback; G Slegers; R A Dierckx
Journal:  Eur J Nucl Med       Date:  2000-11

6.  MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.

Authors:  Jesse J Parry; Rebecca Andrews; Buck E Rogers
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872

7.  An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.

Authors:  C M Korse; B G Taal; J M G Bonfrer; A Vincent; M L van Velthuysen; P Baas
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

8.  Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Authors:  Qing Zhang; Neil E Bhola; Vivian Wai Yan Lui; Doris R Siwak; Sufi M Thomas; Christopher T Gubish; Jill M Siegfried; Gordon B Mills; Dong Shin; Jennifer Rubin Grandis
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

9.  In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.

Authors:  Panteleimon J Marsouvanidis; Marleen Melis; Erik de Blois; Wout A P Breeman; Eric P Krenning; Theodosia Maina; Berthold A Nock; Marion de Jong
Journal:  Cancer Biother Radiopharm       Date:  2014-10-06       Impact factor: 3.099

10.  Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.

Authors:  Nallely Jiménez-Mancilla; Guillermina Ferro-Flores; Clara Santos-Cuevas; Blanca Ocampo-García; Myrna Luna-Gutiérrez; Erika Azorín-Vega; Keila Isaac-Olivé; Miguel Camacho-López; Eugenio Torres-García
Journal:  J Labelled Comp Radiopharm       Date:  2013-07-19       Impact factor: 1.921

View more
  25 in total

1.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

Review 2.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 3.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

4.  Agonist-induced extracellular vesicles contribute to the transfer of functional bombesin receptor-subtype 3 to recipient cells.

Authors:  Zeyuan Wang; Lehao Wu; Huiyu Wang; Yan Zhang; Hua Xiao
Journal:  Cell Mol Life Sci       Date:  2022-01-15       Impact factor: 9.261

Review 5.  Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.

Authors:  Kah Min Yap; Mahendran Sekar; Shivkanya Fuloria; Yuan Seng Wu; Siew Hua Gan; Nur Najihah Izzati Mat Rani; Vetriselvan Subramaniyan; Chandrakant Kokare; Pei Teng Lum; M Yasmin Begum; Shankar Mani; Dhanalekshmi Unnikrishnan Meenakshi; Kathiresan V Sathasivam; Neeraj Kumar Fuloria
Journal:  Int J Nanomedicine       Date:  2021-12-02

6.  The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.

Authors:  Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2022-05-29       Impact factor: 4.402

7.  A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Authors:  Paola Moreno; Samuel A Mantey; Suk H Lee; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Peptides       Date:  2018-02-02       Impact factor: 3.750

8.  Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Terry W Moody; Samuel A Mantey; Robert T Jensen
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-12-17       Impact factor: 4.739

Review 9.  Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.

Authors:  João Franco Machado; João D G Correia; Tânia S Morais
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

Review 10.  Theranostic Advances in Breast Cancer in Nuclear Medicine.

Authors:  Nasim Vahidfar; Ayuob Aghanejad; Hojjat Ahmadzadehfar; Saeed Farzanehfar; Elisabeth Eppard
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.